<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01868945</url>
  </required_header>
  <id_info>
    <org_study_id>2012-10-24-HyD</org_study_id>
    <nct_id>NCT01868945</nct_id>
  </id_info>
  <brief_title>Dose Finding Study in Physically Frail Elderly to Measure 25(OH) Vitamin D Levels After Supplementation With Hy.D Calcifediol 25 SD/S and Vitamin D3</brief_title>
  <acronym>D-DOSE</acronym>
  <official_title>Dose Finding Study in Physically Frail Elderly to Measure 25(OH) Vitamin D Levels After Supplementation With Hy.D Calcifediol 25 SD/S and Vitamin D3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DSM Nutritional Products, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the dose of Hy.D Calcifediol 25 SD/S (a metabolite of
      vitamin D3) which will achieve the range of mean serum 25(OH)D between 75-100nmol/L in
      physically frail elderly people after 24 weeks of daily supplementation with different doses
      of Hy.D Calcifediol 25 SD/S compared to vitamin D3.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean serum 25(OH)D levels in Hy.D and vitamin D3 supplemented groups at baseline</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <description>Outcome measurement: Mean serum 25(OH)D levels at baseline before supplementation of three doses of Hy.D and 1 dose of vitamin D3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean serum 25(OH)D levels in Hy.D and vitamin D3 supplemented groups after 4 weeks</measure>
    <time_frame>4 weeks after initial compound intake</time_frame>
    <description>Outcome measurement: Mean serum 25(OH)D levels after 4 weeks of supplementation of three doses of Hy.D and 1 dose of vitamin D3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean serum 25(OH)D levels in Hy.D and vitamin D3 supplemented groups after 8 weeks</measure>
    <time_frame>8 weeks after initial compound intake</time_frame>
    <description>Outcome measurement: Mean serum 25(OH)D levels after 8 weeks of supplementation of three doses of Hy.D and 1 dose of vitamin D3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean serum 25(OH)D levels in Hy.D and vitamin D3 supplemented groups after 12 weeks</measure>
    <time_frame>12 weeks after initial compound intake</time_frame>
    <description>Outcome measurement: Mean serum 25(OH)D levels after 12 weeks of supplementation of three doses of Hy.D and 1 dose of vitamin D3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean serum 25(OH)D levels in Hy.D and vitamin D3 supplemented groups after 16 weeks</measure>
    <time_frame>16 weeks after initial compound intake</time_frame>
    <description>Outcome measurement: Mean serum 25(OH)D levels after 16 weeks of supplementation of three doses of Hy.D and 1 dose of vitamin D3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean serum 25(OH)D levels in Hy.D and vitamin D3 supplemented groups after 20 weeks</measure>
    <time_frame>20 weeks after initial compound intake</time_frame>
    <description>Outcome measurement: Mean serum 25(OH)D levels after 20 weeks of supplementation of three doses of Hy.D and 1 dose of vitamin D3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean serum 25(OH)D levels in Hy.D and vitamin D3 supplemented groups after 24 weeks</measure>
    <time_frame>24 weeks after initial compound intake</time_frame>
    <description>Outcome measurement: Mean serum 25(OH)D levels after 24 weeks of supplementation of three doses of Hy.D and 1 dose of vitamin D3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Descriptive: 25(OH)D3 serum steady state reached?</measure>
    <time_frame>0, 4, 8, 12, 16, 20, 24 weeks after study start</time_frame>
    <description>Assessment if 25(OH)D3 serum levels will reach a steady state after 24 weeks supplementation of 3 doses of Hy.D and 1 dose of vitamin D3</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Pre-frail Elderly</condition>
  <condition>Frail Elderly</condition>
  <arm_group>
    <arm_group_label>5 µg/day Hy.D Calcifediol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10 µg/day Hy.D Calcifediol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>15 µg/day Hy.D Calcifediol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>20 µg/day vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>5 µg/day Hy.D Calcifediol</intervention_name>
    <description>5 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks</description>
    <arm_group_label>5 µg/day Hy.D Calcifediol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>10 µg/day Hy.D Calcifediol</intervention_name>
    <description>10 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks</description>
    <arm_group_label>10 µg/day Hy.D Calcifediol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>15 µg/day Hy.D Calcifediol</intervention_name>
    <description>15 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks</description>
    <arm_group_label>15 µg/day Hy.D Calcifediol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>20 µg/day vitamin D3</intervention_name>
    <description>20 µg/day vitamin D3 taken together with breakfast for a total period of 24 weeks</description>
    <arm_group_label>20 µg/day vitamin D3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  25(OH)D levels between 25 - 50 nmol/L;

          -  Age 65 and older;

          -  Physically frail, based on the criteria designed by Fried et al. [1]. Frailty will be
             defined as a clinical syndrome in which one or more of the following criteria are
             present: unintentional weight loss (4.5 kg in past year), selfreported exhaustion
             (CES-D questionnaire), weakness (grip strength), slow walking speed and low physical
             activity (Minnesota questionnaire). These criteria are easily assessable and have been
             commonly used to determine frailty;

          -  Men and women;

          -  Body mass index between 20 and 35 kg/m2 (used for stratification);

          -  Willingness and ability to comply with the protocol.

        Exclusion Criteria:

          -  Medical Illness: malabsorption syndrome: known intestinal malabsorption, celiac
             diseases, inflammatory bowel disease; diseases that may enhance serum calcium
             concentration: sarcoidosis, lymphoma, kidney stone in the last 10 years, primary
             hyperparathyroidism; abnormal indices of calcium metabolism, uncontrolled
             hypocalcaemia; diagnosed renal insufficiency, diagnosed cancer, diagnosed liver
             failure.

          -  Hypercalcemia : serum calcium adjusted for albumin of &gt; 2.6 nmol/L.

          -  Medication: bisphosphonate or Parathyroid hormone (PTH) treatment, tuberculostatics,
             epilepsy medication, interfering with vitamin D metabolism and vitamin D
             supplementation.

          -  Use of vitamin D supplementation in the last three months (excluding multivitamin
             supplementation).

          -  Not willing to stop the use of multivitamin supplementation during the study.

          -  (Expected) increase in exposure to sunlight (e.g. travelling to a sunny resort).

          -  Patient heavily consumes alcohol containing products defined as greater than (&gt;) 3
             drinks (beer, wine, or distilled spirits) of alcoholic beverages per day.

          -  Donating blood in the period of 2 months before, until 1 month after the end of the
             study.

          -  Planned surgery.

          -  Participation in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisette De Groot, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wageningen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Tieland, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wageningen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luc van Loon, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wageningen University</name>
      <address>
        <city>Wageningen</city>
        <zip>6700</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2013</study_first_submitted>
  <study_first_submitted_qc>May 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D3</keyword>
  <keyword>Calcifediol 25</keyword>
  <keyword>Frail</keyword>
  <keyword>Dose-response</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

